Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma
Julie Valentin(Centre Hospitalier Universitaire de Bordeaux), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), Thomas Ferté(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), E. Gérard(Université de Bordeaux), M. Beylot‐Barry, L. Dousset(Centre Hospitalier Universitaire de Bordeaux), S. Prey(Centre Hospitalier Universitaire de Bordeaux)
Cited by 32
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k